T helper cell type 2 immune response (Th2 immune response)

The **T helper cell type 2 (Th2) immune response** is not a single molecular target but rather describes an orchestrated set of cellular activities mediated by the Th2 subset of CD4+ T lymphocytes. Upon activation by antigen-presenting cells and specific cytokine environments, naïve CD4+ T cells differentiate into Th2 cells. These cells secrete characteristic cytokines—including interleukin 4 (IL‑4), interleukin 5 (IL‑5), interleukin 6 (IL‑6), interleukin 9 (IL‑9), interleukin 13 (IL‑13), and sometimes IL‑17E/25—which collectively drive antibody production by B cells, promote eosinophil recruitment and activation, stimulate mast cell proliferation, induce mucus production in tissues such as airways, and inhibit some macrophage functions[1][5]. The **Th2 immune response** is essential for protection against extracellular parasites like helminths but also underlies allergic diseases such as asthma and atopic dermatitis when dysregulated. Overactivation can contribute to autoimmune pathology. Because this term refers to an entire immunological process rather than a discrete protein or receptor targetable by drugs directly, it should not be considered a canonical therapeutic target itself; instead individual components—such as specific cytokines or their receptors—are targeted therapeutically[1][3]. **Note:** This entry is marked *incorrect* because \"T helper cell type 2 immune response\" does not refer to a single molecular entity suitable for structured drug-target information—it describes an immunological process involving multiple molecules/cells. For structured data purposes on drug targets you should use specific molecules within this pathway such as \"Interleukin‑4 receptor\" or \"Interleukin‑13\".

Other names

Th2 responseType 2 helper T cell immune responseT helper type 2 cell-mediated immunity

Drugs target cytokines produced by Th2 cells—e.g., IL‑4/IL‑13 antagonists block their signaling pathways.